PMID- 33378938
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220531
IS  - 1551-0018 (Electronic)
IS  - 1547-1063 (Linking)
VI  - 17
IP  - 6
DP  - 2020 Nov 13
TI  - Downregulation of CDC14B in 5218 breast cancer patients: A novel prognosticator 
      for triple-negative breast cancer.
PG  - 8152-8181
LID - 10.3934/mbe.2020414 [doi]
AB  - Breast cancer is the most common female malignancy worldwide and the prognosis of 
      triple-negative breast cancer (TNBC) and advanced breast cancer patients is 
      unsatisfying. The exploration of novel prognostic indicators and appropriate 
      targets is crucial for improving the treatment outcomes of breast cancer 
      patients. The cell division cycle protein 14B (CDC14B) is known for its roles in 
      cell cycle control, but its expression status and molecular function in breast 
      cancer is unknown. This study explores the expression patterns and clinical 
      values of CDC14B in breast cancer tissues. For this research, the authors 
      downloaded gene microarrays and RNA sequencing datasets to examine the expression 
      levels of CDC14B in 5218 breast cancer tissues, comparing them to the expression 
      levels in 1176 normal breast tissues. The relationships between CDC14B and 
      clinicopathologic characteristics of breast cancer were also addressed. The 
      mutation conditions of CDC14B were then clarified using cBioPortal. Finally, 
      differentially expressed genes and co-expressed genes related to CDC14B were 
      filtered using the Limma-Voom package. These genes were intersected to conduct 
      functional annotations and to construct a protein-protein interaction network. It 
      was observed that CDC14B was significantly downregulated in breast cancer tissues 
      but not in normal breast tissues (standardized mean difference = -1.17 
      [-1.50--0.85], area under the curve = 0.88). In addition, CDC14B downregulation 
      was correlated with the poor prognosis of TNBC patients (hazard ratios < 1; p < 
      0.05). Amplification was detected to be the most frequent alteration of CDC14B. 
      The presence of this alteration forecasted unfavourable overall survival outcomes 
      in breast cancer patients (p < 0.05). Dysregulated genes that co-expressed with 
      CDC14B were pivotal in cell cycle (namely mitotic-nuclear division and DNA 
      packaging complex) and cancer-related signaling pathways (namely the peroxisome 
      proliferators activated receptor [PPAR] signalling pathway and the AMP-activated 
      protein kinase [AMPK] signalling pathway). Moreover, the genes ADIPOQ and CCNE2 
      were identified as two promising prognostic factors in breast cancer. In summary, 
      CDC14B was downregulated in breast cancer tissue and may be a promising hallmark 
      in TNBC patients. The dysregulated genes co-expressed with CDC14B may play an 
      important role in the development of breast cancer through PPAR and AMPK 
      signalling pathways.
FAU - Li, Jian-Di
AU  - Li JD
AD  - Department of Breast Surgery, Guangxi Medical University Cancer Hospital, No.71 
      Hedi Rd, Nanning, Guangxi Zhuang Autonomous Region 530021, China.
FAU - Chen, Gang
AU  - Chen G
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      No. 6 Shuangyong Rd, Nanning, Guangxi Zhuang Autonomous Region 530021, China.
FAU - Wu, Mei
AU  - Wu M
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      No. 6 Shuangyong Rd, Nanning, Guangxi Zhuang Autonomous Region 530021, China.
FAU - Huang, Yu
AU  - Huang Y
AD  - Department of Pathology, First Affiliated Hospital of Guangxi University of 
      Chinese Medicine, No. 89-9 Dongge Rd, Nanning, Guangxi Zhuang Autonomous Region 
      530023, China.
FAU - Tang, Wei
AU  - Tang W
AD  - Department of Breast Surgery, Guangxi Medical University Cancer Hospital, No.71 
      Hedi Rd, Nanning, Guangxi Zhuang Autonomous Region 530021, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Math Biosci Eng
JT  - Mathematical biosciences and engineering : MBE
JID - 101197794
RN  - EC 3.1.3.48 (CDC14B protein, human)
RN  - EC 3.1.3.48 (Dual-Specificity Phosphatases)
SB  - IM
MH  - Down-Regulation
MH  - Dual-Specificity Phosphatases/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Protein Interaction Maps
MH  - Signal Transduction
MH  - *Triple Negative Breast Neoplasms/genetics
OTO - NOTNLM
OT  - CDC14B
OT  - RNA sequencing
OT  - breast cancer
OT  - clinical utility
OT  - genetic mutation
OT  - microarray
OT  - signaling pathway
EDAT- 2021/01/01 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/12/31 01:00
PHST- 2020/12/31 01:00 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.3934/mbe.2020414 [doi]
PST - ppublish
SO  - Math Biosci Eng. 2020 Nov 13;17(6):8152-8181. doi: 10.3934/mbe.2020414.